Gastrointestinal Stroma Tumor-A Case Report and Literature Review

胃腸間質細胞瘤－病例報告及文獻回顧

黃英傑(Ying C. Huang) ； 蔡崇榮(Tsung-Jung Tsai) ； 江慶鐘(Ching-Chung Chiang) ； 董俊良(Chun-Liang Tung)

《東港安泰醫護雜誌》 10卷3期 (2004/09) Pp. 159-166

https://doi.org/10.7078/TSMHMNJ.200409.0159

摘要

胃腸間質細胞瘤是一少見、但可以為惡性表現的腫瘤。這種腫瘤乃是由源自胃腸道或是網膜的間質梭狀細胞或是類上皮細胞所組成。患者通常是因為胃腸道出血、非特異性腹痛或腹部不適、摸到腫瘤、或者根本就是無意間被發現。因為腫瘤細胞對CD117呈陽性免疫反應，藉著特殊組織化學染色可以確診此病。大部分胃腸間質細胞瘤的起因來自c-kit腫瘤原型基因的突變。此基因突變會活化KIT受體，進一步導致細胞受刺激而沒有限制地增生。以前此病一但轉移或是術後復發，預後都很差。近年來因為Imatinib抑制KIT受體的標地治療而有大幅改觀。即使是晚期患者也能夠獲得相當的腫瘤抑制及臨床助益。

關鍵字

胃腸間質細胞瘤

並列摘要

Gastrointestinal stromal tumor (GIST) is a rare, but potentially aggressive tumor. This tumor is composed with mesenchymal spindle or epithelioid cells arising in the wall of the gastrointestinal tract or omentum. Patients can present with gastrointestinal hemorrhage, non-specific abdominal pain or discomfort, palpable mass or found accidentally. With histochemical staining, definite diagnosis can be obtained from its consistent immunoreactivity for CD117. Most of the GISTs come from unopposed stimulation of cell growth which is resulted from activation of the KIT receptor secondary to mutation in the c-kit proto-oncogene. Although the prognosis was poor before in recurred or advanced stages. Targeted therapy of KIT inhibition by Imatinib will change the situations. Patients with advanced GISTs can gain clinical benefit and significant antitumour responses with Imatinib.

並列關鍵字

Gastrointestinal stromal tumor GIST